Related Experiment Video
Updated: Jun 10, 2025
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Targeting Nrf2 signaling in dry eye.
Yu-Nuo Zhang1,2, Wei-Jie Ouyang1, Jiao-Yue Hu1,3
1Xiamen University Affiliated Xiamen Eye Center; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen 361005, Fujian Province, China.
Activating the Nrf2 antioxidant pathway shows promise for treating dry eye disease. This pathway helps protect ocular surface tissues from oxidative stress, improving patient quality of life.
Area of Science:
- Ophthalmology
- Cell Biology
- Pharmacology
Background:
- Dry eye disease is a prevalent ocular surface condition causing tissue damage and discomfort.
- Oxidative stress is a key factor in dry eye pathogenesis, impacting patient quality of life.
- The body's primary antioxidant pathway, Nrf2, offers a potential therapeutic target.
Purpose of the Study:
- To review the role of the Nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway in dry eye disease.
- To explore the mechanisms by which Nrf2 activation may treat dry eye.
- To summarize current drugs targeting the Nrf2 pathway for dry eye treatment.
Main Methods:
- Literature review of studies on dry eye, oxidative stress, and the Nrf2 pathway.
- Analysis of Nrf2 pathway structure, function, and its role in ocular surface homeostasis.
- Compilation of research on therapeutic agents that modulate Nrf2 activity.
Main Results:
- Oxidative stress significantly contributes to dry eye pathogenesis.
- Nrf2 pathway activation demonstrates potential in mitigating dry eye symptoms and damage.
- Several drugs targeting Nrf2 are being investigated for dry eye treatment.
Conclusions:
- The Nrf2 signaling pathway is a critical regulator of antioxidant defense in dry eye.
- Targeting Nrf2 activation presents a promising therapeutic strategy for managing dry eye disease.
- Further research into Nrf2-activating drugs could lead to novel dry eye treatments.
